Castle Biosciences, Inc. (Nasdaq: CSTL), a business using ingenious diagnostics to change illness management and enhance client results, today revealed that Derek Maetzold, president and president, and Frank Stokes, primary monetary officer, are arranged to provide a business introduction at the 24 th Yearly Needham Development Conference on Monday, Jan. 10, 2022, at 12: 30 p.m. Eastern time.
A live audio webcast of the business’s discussion will be readily available by checking out Castle Biosciences’ site at https://ir.castlebiosciences.com/events-presentations/default.aspx A replay of the webcast will be readily available for 2 weeks following the conclusion of the live broadcast.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics business that offers individualized, scientifically actionable info to clinicians and clients to notify treatment choices and enhance health results. The Business is concentrated on changing the illness management paradigm in skin cancer and other illness with high medical requirement by leveraging innovative innovations for its portfolio of ingenious diagnostic tests.
Castle’s present portfolio includes tests for skin cancers, uveal cancer malignancy and Barrett’s esophagus. In addition, the Business has active research study and advancement programs for tests in other illness with high medical requirement, including its test in advancement to anticipate systemic treatment reaction in clients with moderate-to-severe psoriasis, atopic dermatitis and associated conditions. To find out more, please see www.CastleBiosciences.com and get in touch with us on LinkedIn, Facebook, Twitter and Instagram
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Cancer malignancy, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq and TissueCypher are hallmarks of Castle Biosciences, Inc.
View source variation on businesswire.com: https://www.businesswire.com/news/home/20211228005006/ en/